Algert Global’s NEVRO CORP. NVRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-41,173
| Closed | -$240K | – | 1377 |
|
|
2025
Q1 | $240K | Sell |
41,173
-20,060
| -33% | -$106K | 0.01% | 1051 |
|
|
2024
Q4 | $228K | Buy |
61,233
+4,120
| +7% | +$19K | 0.01% | 1053 |
|
|
2024
Q3 | $319K | Sell |
57,113
-159,459
| -74% | -$1.12M | 0.01% | 985 |
|
|
2024
Q2 | $1.82M | Buy |
216,572
+78,895
| +57% | +$841K | 0.06% | 496 |
|
|
2024
Q1 | $1.99M | Buy |
+137,677
| New | +$2.28M | 0.08% | 418 |
|
|
2023
Q4 | – | Sell |
-28,867
| Closed | -$555K | – | 1287 |
|
|
2023
Q3 | $555K | Sell |
28,867
-14,730
| -34% | -$314K | 0.03% | 711 |
|
|
2023
Q2 | $1.11M | Buy |
43,597
+8,830
| +25% | +$255K | 0.05% | 623 |
|
|
2023
Q1 | $1.26M | Buy |
34,767
+728
| +2% | +$25.6K | 0.06% | 542 |
|
|
2022
Q4 | $1.35M | Sell |
34,039
-1,640
| -5% | -$68.2K | 0.07% | 442 |
|
|
2022
Q3 | $1.66M | Buy |
35,679
+20,789
| +140% | +$965K | 0.1% | 339 |
|
|
2022
Q2 | $653K | Buy |
+14,890
| New | +$819K | 0.05% | 660 |
|
|
2021
Q4 | – | Sell |
-2,814
| Closed | -$327K | – | 1144 |
|
|
2021
Q3 | $327K | Buy |
+2,814
| New | +$368K | 0.04% | 729 |
|
Other funds holding NVRO
Algert Global's NVRO Position: Q2 2025 in Review
Algert Global sold out of NEVRO CORP. (NVRO) in Q2 2025, closing a stake of 41,173 shares — an estimated $240K sold.
Algert Global first reported a position in NVRO in Q3 2021 and held it in 12 quarters. The position peaked at $1.99M in Q1 2024. 1 fund tracked by Wall St. Rank holds NVRO as of Q2 2025.
- Algert Global reported no remaining NEVRO CORP. position as of Q2 2025 after selling out during the quarter.
- Algert Global sold 41,173 NEVRO CORP. shares in Q2 2025, an estimated $240K.
- Algert Global first reported a position in NEVRO CORP. in Q3 2021 and held it in 12 quarters.
- Algert Global's NEVRO CORP. position peaked at $1.99M in Q1 2024.
- 1 fund tracked by Wall St. Rank held NEVRO CORP. as of Q2 2025.
Based on Algert Global's 13F filing for Q2 2025, filed 14 Aug 2025.